[{"id":"97ed81de-4986-4ca6-9f9a-c890f0cf6354","acronym":"","url":"https://clinicaltrials.gov/study/NCT05765851","created_at":"2023-03-13T15:02:22.751Z","updated_at":"2025-02-25T15:00:49.420Z","phase":"Phase 1","brief_title":"A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05765851","lead_sponsor":"Daiichi Sankyo","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 mutation • HER-2 expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-30"}]